Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20108 in Advanced Solid Tumors
NCT06936735Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2025
- Primary completion
- Aug 2028
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of HS-20108 in solid tumor, small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) (9 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Maximum Tolerated Dose or Maximum Administered Dose at 48 months. Started May 2025; status: recruiting.
02
Drugs
HS-20108
03
Conditions
solid tumorsmall cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT06936735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06936735.